Variability in response to albuminuria-lowering drugs: true or random? - Wikidata - awgldk - TriplyDB

Variability in response to albuminuria-lowering drugs: true or random?

Variability in response to albuminuria-lowering drugs: true or random?

http://www.wikidata.org/entity/Q55140376

about

Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.How to measure and monitor albuminuria in healthy toddlers?

P2860

Q38689726-965BDBCB-DFD5-4BBE-8841-A70F88C2F146 Q38906470-FF4CE45E-BC0C-4417-A93E-9B53E59FD1CB Q55496622-E5172F37-16EA-4B4B-B3E5-26FC64D66BAC

P2860

Variability in response to albuminuria-lowering drugs: true or random?

http://www.wikidata.org/entity/Q55140376

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Variability in response to albuminuria-lowering drugs: true or random?

@en

Variability in response to albuminuria-lowering drugs: true or random?

@nl

type

label

Variability in response to albuminuria-lowering drugs: true or random?

@en

Variability in response to albuminuria-lowering drugs: true or random?

@nl

prefLabel

Variability in response to albuminuria-lowering drugs: true or random?

@en

Variability in response to albuminuria-lowering drugs: true or random?

@nl

P1433

Q55140376-61501716-2666-4E29-A12B-C40DE1613E66

P1476

Q55140376-7FA4C06B-9EB4-4DDE-93BB-55A7841A3143

P2093

Q55140376-15096ADA-1A5A-4866-83AB-CA5A6F022043

Q55140376-32B4D00F-4B8A-407A-9733-E16B854F3CD0

Q55140376-354465E2-4370-4CC4-80B2-C7D11F9DB9E4

Q55140376-640C1BC4-AB6C-42CF-AD84-F9D6C1DAA820

Q55140376-A3993364-1EAB-4AA5-AB44-10D56F9DBF9C

P2860

Q55140376-189D9930-8EC9-466E-83A9-406DE4ADE912

Q55140376-21553310-9E80-4A20-8BCA-3DD0908F772C

Q55140376-318C39C7-0D06-4AA0-93C4-E0B295407C2A

Q55140376-3D911CE7-EF3E-4E78-B5E6-F544EC3AC2BF

Q55140376-47B90540-40AA-4DC3-B150-13B7F12077D7

Q55140376-57DC0086-530A-4827-A859-90A1B82715D0

Q55140376-73780CC7-E786-4F4C-85FD-5907C0B7C04D

Q55140376-7C3936C4-E3EA-43E8-A15F-C65538581C51

Q55140376-7E331D9A-11BF-4267-A85A-101A52F8AAF6

Q55140376-7EA157EE-9286-41C0-8274-273C3B031E9B

P304

Q55140376-A3AC7BA6-39CE-42CD-9A5B-7433FA7DE193

P31

Q55140376-ED7F0F57-9503-4CE1-BD71-3172106E417E

P356

Q55140376-C3D8878C-BAD9-4F3D-8003-49B6561A8C3C

P407

Q55140376-6089027C-4490-448B-AD99-311F5B7B50DD

P433

Q55140376-A42CD45B-8698-4504-8521-D62DB563B8A0

P478

Q55140376-AF69DA01-683B-47CA-92B6-C9BA76242595

P50

Q55140376-3AAFB2C3-E675-4A82-85ED-2D4E881AA788

Q55140376-BF553BAA-FB92-4FA3-906C-C7F7F4C2260D

P577

Q55140376-5576B542-136D-47F9-81C1-E95193082E64

P698

Q55140376-48BBA88B-3AA6-4626-8EBE-B90850A93C82

P932

Q55140376-C550DB40-AE79-4FA9-9E7C-AAD9FF0E3F9C

P356

P1433

British Journal of Clinical Pharmacology

P1476

Variability in response to albuminuria-lowering drugs: true or random?

@en

P2093

Dick de Zeeuw

http://www.w3.org/2001/XMLSchema#string

Gozewijn D Laverman

http://www.w3.org/2001/XMLSchema#string

Hiddo J L Heerspink

http://www.w3.org/2001/XMLSchema#string

Ron T Gansevoort

http://www.w3.org/2001/XMLSchema#string

Sergei I Petrykiv

http://www.w3.org/2001/XMLSchema#string

P2860

Supramaximal dose of candesartan in proteinuric renal disease

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy

The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors.

Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials.

Preventing microalbuminuria in type 2 diabetes.

P304

1197-1204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13217

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P50

Frederik Persson

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28002889

http://www.w3.org/2001/XMLSchema#string

P932

5427237

http://www.w3.org/2001/XMLSchema#string